Meyka Pro banner
Opus Genetics, Inc.

Opus Genetics, Inc. (IRD) Stock Overview

Explore Opus Genetics, Inc.’s financial performance, market position, analyst ratings, and future outlook.

IRD●NASDAQ
HealthcareBiotechnology
$4.65
$0.24(5.44%)
U.S. Market opens in 4h 32m

Opus Genetics, Inc. (IRD)

Meyka AI Score

Z

Key Financials

Market Cap368.2M
P/E Ratio-3.69
EPS (TTM)$-1.28
ROE11.48%
Fundamental Analysis

AI Price Forecasts

1 Month$4.25
3 Months$5.54
1 Year Target$5.80

IRD Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Opus Genetics, Inc. (NASDAQ: IRD) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Opus Genetics, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of IRD on the NASDAQ shows an RSI of 49.17, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $5.80 for the NASDAQ listing.

Key metrics behind Opus Genetics, Inc.'s NASDAQ-traded stock include a P/E ratio of -3.69 and a market capitalization of 368.2M. Combined with our AI analysis, these give both institutional and retail investors a clear view of IRD on the NASDAQ.

Price Performance (NASDAQ: IRD)

1-Day Change
4.26%
5-Day Change
1.97%
1-Month Change
-18.85%
3-Month Change
15.67%
6-Month Change
-15.45%
Year-to-Date (YTD) Change
131.34%
1-Year Change
133.67%
3-Year Change
260.47%
5-Year Change
260.47%
All-Time (Max) Change
260.47%

Contact Information

248 957 9024
8 Davis Drive, Durham, NC, 27713

Company Facts

280 Employees
IPO DateJan 19, 2015
CountryUS
Actively Trading

Frequently Asked Questions